Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV001335994 | SCV001529262 | uncertain significance | Jawad syndrome | 2018-05-10 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Genetic Services Laboratory, |
RCV001820030 | SCV002068686 | uncertain significance | not specified | 2019-02-26 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001865841 | SCV002147749 | uncertain significance | not provided | 2022-09-27 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 716 of the RBBP8 protein (p.Glu716Lys). This variant is present in population databases (rs148713374, gnomAD 0.2%). This variant has not been reported in the literature in individuals affected with RBBP8-related conditions. ClinVar contains an entry for this variant (Variation ID: 1033552). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002486342 | SCV002783451 | uncertain significance | Jawad syndrome; Seckel syndrome 2 | 2022-03-28 | criteria provided, single submitter | clinical testing |